Mark Anthony McCamish, Director at AVADEL PHARMACEUTICALS PLC (AVDL), sold 75,000 shares at $14.53 ($1.1M) on 2023-12-28, disclosed to the SEC on 2023-12-29.
Scheduled sale ($1.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| FTSV | SELL | 2020-04-03 | $6.2M | — | Filing → |
| FTSV | SELL | 2019-06-27 | $181K | — | Filing → |
| FTSV | SELL | 2019-06-24 | $183K | — | Filing → |